SCHEMBL19407482

SCHEMBL19407482

CC(C)(C)OC(=O)N[C@H](Cc1ccc2ccccc2n1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRB1 P18505 1/20 0.45
GABRB2 P47870 1/20 0.45
CTSS P25774 3/20 0.45
CTSK P43235 2/20 0.45
ALDH1A1 P00352 2/20 0.44
ALOX5AP P20292 2/20 0.43
CYP1A2 P05177 1/20 0.43
CTSB P07858 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
ATM Q13315 1/20 0.42
CYSLTR2 Q9NS75 1/20 0.42
CYSLTR1 Q9Y271 1/20 0.42
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28824776 1.00 GABRB1 (0.45) GABRB1GABRB2CTSSCTSKALDH1A1
SCHEMBL29858176 1.00 GABRB1 (0.45) GABRB1GABRB2CTSSCTSKALDH1A1
SCHEMBL29858135 0.88 CYP1A2 (0.47) ALOX5APCYP1A2GAACYSLTR2CYSLTR1
SCHEMBL21467676 0.88 CYP1A2 (0.47) ALOX5APCYP1A2GAACYSLTR2CYSLTR1
SCHEMBL28824775 0.88 CYP1A2 (0.47) ALOX5APCYP1A2GAACYSLTR2CYSLTR1
SCHEMBL14265380 0.85 ACE (0.53) CTSSCTSKCYP1A2CTSBMEN1
SCHEMBL21467795 0.85 KMT2A (0.49) ALDH1A1CYP1A2MEN1KMT2ANPC1
SCHEMBL29858159 0.85 KMT2A (0.49) ALDH1A1CYP1A2MEN1KMT2ANPC1
SCHEMBL2300113 0.85 ACE (0.53) CTSSCTSKCYP1A2CTSBMEN1
SCHEMBL28824795 0.85 KMT2A (0.49) ALDH1A1CYP1A2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563045-B Pd (II) -catalysed enantioselective beta-methylene C (sp) 3 ) -H bond activation 斯克里普斯研究学院 2022-08-23 CN disclosed
US-11186563-B2 Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation THE SCRIPPS RESEARCH INSTITUTE (US) 2021-11-30 US disclosed
US-20190315710-A1 Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation THE SCRIPPS RESEARCH INSTITUTE 2019-10-17 US disclosed
WO-2017165304-A2 Pd(II)-CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C(sp3)-H BOND ACTIVATION THE SCRIPPS RESEARCH INSTITUTE (US) 2017-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315710-A1 Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation POLQ, AP3D1, AP3S1 GABRB1 750/4885GABRB2 502/4885CTSS 768/4885
US-11186563-B2 Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation POLQ, AP3D1, AP3S1 GABRB1 835/4885GABRB2 570/4885CTSS 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.